Randomized phase II trial of S-1 plus irinotecan versus S-1 plus paclitaxel as first-line treatment for advanced gastric cancer (OGSG0402): Final report

被引：1
|
作者：
Kishimoto, T.
Imamura, H.
Uedou, F.
Fujitani, K.
Iijima, S.
Takiuchi, H.
Imano, M.
Shimokawa, T.
Kurokawa, Y.
Furukawa, H.
机构：
[1] Sakai Municipal Hosp, Sakai, Osaka, Japan
[2] Osaka Med Ctr Canc & Cardiovasc Dis, Osaka, Japan
[3] Natl Osaka Med Ctr, Osaka, Japan
[4] Minoh City Hosp, Mino, Japan
[5] Osaka Med Coll Hosp, Osaka, Japan
[6] Kinki Univ, Osaka, Japan
[7] Yamanashi Univ, Kofu, Yamanashi 400, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.4015
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4015
引用
收藏
页数：1
相关论文
共 50 条
  • [41] S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial
    Hironaka, Shuichi
    Sugimoto, Naotoshi
    Yamaguchi, Kensei
    Moriwaki, Toshikazu
    Komatsu, Yoshito
    Nishina, Tomohiro
    Tsuji, Akihito
    Nakajima, Takako Eguchi
    Gotoh, Masahiro
    Machida, Nozomu
    Bando, Hideaki
    Esaki, Taito
    Emi, Yasunori
    Sekikawa, Takashi
    Matsumoto, Shigemi
    Takeuchi, Masahiro
    Boku, Narikazu
    Baba, Hideo
    Hyodo, Ichinosuke
    LANCET ONCOLOGY, 2016, 17 (01): : 99 - 108
  • [42] Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study)
    Koizumi, W.
    Takiuchi, H.
    Yamada, Y.
    Boku, N.
    Fuse, N.
    Muro, K.
    Komatsu, Y.
    Tsuburaya, A.
    ANNALS OF ONCOLOGY, 2010, 21 (05) : 1001 - 1005
  • [43] Phase II trial of S-1 plus cisplatin for neoadjuvant treatment of locally advanced gastric cancer
    Omura, K.
    Yoshikawa, T.
    Nashirnoto, A.
    Ohta, K.
    Kinoshita, K.
    Murakarni, N.
    Yarnaue, H.
    Nakajima, T.
    ANNALS OF ONCOLOGY, 2008, 19 : 40 - 40
  • [44] Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial)
    Lee, Keun-Wook
    Chung, Ik-Joo
    Ryu, Min-Hee
    Park, Young Iee
    Nam, Byung-Ho
    Oh, Ho-Suk
    Lee, Kyung Hee
    Han, Hye Sook
    Seo, Bong-Gun
    Jo, Jae-Cheol
    Lee, Hyo Rak
    Kim, Jin Won
    Park, Sook Ryun
    Cho, Sang Hee
    Kang, Yoon-Koo
    GASTRIC CANCER, 2021, 24 (01) : 156 - 167
  • [45] Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial)
    Keun-Wook Lee
    Ik-Joo Chung
    Min-Hee Ryu
    Young Iee Park
    Byung-Ho Nam
    Ho-Suk Oh
    Kyung Hee Lee
    Hye Sook Han
    Bong-Gun Seo
    Jae-Cheol Jo
    Hyo Rak Lee
    Jin Won Kim
    Sook Ryun Park
    Sang Hee Cho
    Yoon-Koo Kang
    Gastric Cancer, 2021, 24 : 156 - 167
  • [46] RANDOMIZED PHASE II CLINICAL TRIAL OF TAILORED IRINOTECAN (CPT-11) PLUS S-1 VERSUS S-1 IN PATIENTS WITH ADVANCED OR RECURRENT GASTRIC CARCINOMA AS THE FIRST-LINE CHEMOTHERAPY (THE JAPANESE FOUNDATION FOR MULTIDISCIPLINARY TREATMENT OF CANCER, JFMC31-0301)
    Takahashi, Y.
    Komatsu, Y.
    Kitajima, M.
    Kubota, T.
    Saji, S.
    Nishiyama, M.
    Kimura, Y.
    Oda, H.
    Tajima, Y.
    Miki, H.
    ANNALS OF ONCOLOGY, 2008, 19 : 172 - 172
  • [47] Comparison of early tumor shrinkage between oxaliplatin plus S-1 and cisplatin plus S-1 in first-line chemotherapy with advanced gastric cancer.
    Osumi, Hiroki
    Takahari, Daisuke
    Shinozaki, Eiji
    Chin, Keisho
    Ogura, Mariko
    Nakayama, Izuma
    Matsushima, Tomohiro
    Wakatsuki, Takeru
    Ichimura, Takashi
    Suenaga, Mitsukuni
    Yamaguchi, Kensei
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [48] Clinical observation of nab-paclitaxel plus S-1 as first-line chemotherapy for advanced gastric cancer.
    Hu, Yi
    Sun, Danyang
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [49] Safety analysis of weekly paclitaxel plus S-1 versus paclitaxel plus 5-fluorouracil/calcium folinate as first-line therapy in advanced gastric cancer: a multicenter open random phase II trial
    Deng, Ting
    Xu, Nong
    Xiong, Jian-Ping
    Yan, Zhao
    Zhuang, Zhi-Xiang
    Yu, Zhuang
    Wan, Hui-Ping
    Zhang, Yang
    Huang, Ding-Zhi
    Zheng, Rong-Sheng
    Guo, Zeng-Qing
    Hu, Chun-Hong
    Wang, Mei-Ling
    Yu, Zhong-He
    Yao, Yang
    Meng, Ji-Chang
    Ba, Yi
    JOURNAL OF CHEMOTHERAPY, 2013, 25 (01) : 56 - 59
  • [50] Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002)
    Narahara, Hiroyuki
    Iishi, Hiroyasu
    Imamura, Hiroshi
    Tsuburaya, Akira
    Chin, Keisho
    Imamoto, Haruhiko
    Esaki, Taito
    Furukawa, Hiroshi
    Hamada, Chikuma
    Sakata, Yuh
    GASTRIC CANCER, 2011, 14 (01) : 72 - 80
12345